Glucotrack's Lōkahi Therapeutic Subsidiary Initiates Good Manufacturing Practice Production Campaign For LT-100
Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the
Glucotrack's bee-venom medicine is now being made in an official, approved factory way. This is an important step forward, but it's still early—the company has to prove the medicine actually works before people can buy it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.